Accéder au contenu
Merck
Toutes les photos(3)

Key Documents

S8442

Sigma-Aldrich

SU 5416

≥98% (HPLC), powder, neuronal nitric oxide synthase inhibitor

Synonyme(s) :

1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C15H14N2O
Numéro CAS:
Poids moléculaire :
238.28
Numéro MDL:
Code UNSPSC :
51111800
ID de substance PubChem :
Nomenclature NACRES :
NA.77

product name

SU 5416, ≥98% (HPLC)

Niveau de qualité

Pureté

≥98% (HPLC)

Forme

powder

Couleur

yellow to yellow-orange

Pf

221-222 °C

Solubilité

DMSO: 20 mg/mL, clear (warmed)
H2O: insoluble

Température de stockage

−20°C

Chaîne SMILES 

Cc1cc(C)c(C=C2C(=O)Nc3ccccc23)[nH]1

InChI

1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8+

Clé InChI

WUWDLXZGHZSWQZ-XYOKQWHBSA-N

Description générale

SU 5416 is a vascular endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2 inhibitor. SU 5416 is known to prevent tumor growth and tumor angiogenesis. SU 5416 inhibits the activity of neuronal nitric oxide synthase and protects the neuronal cells from nitric oxide-mediated neurotoxicity. It also acts as an agonist of aryl hydrocarbon receptor and may be an effective clinical agent for treating autoimmune diseases and transplant rejection.

Application

SU 5416 has been used to treat HUVEC cells before the tube formation assay to assess its impact on the network generated from tube formation. to induce pulmonary hypertension (PH) in mice to serve as an experimental model

Actions biochimiques/physiologiques

SU 516 inhibits the activity of neuronal nitric oxide synthase and protects the neuronal cells from nitric oxide-mediated neurotoxicity.1 It also acts an agonist of aryl hydrocarbon receptor and is an effective clinical agent for treating autoimmune diseases and transplant rejection.2
SU 5416 is a vascular endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2 inhibitor.

Caractéristiques et avantages

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Joshua D Mezrich et al.
PloS one, 7(9), e44547-e44547 (2012-09-13)
The experimental compound SU5416 went as far as Phase III clinical trials as an anticancer agent, putatively because of its activity as a VEGFR-2 inhibitor, but showed poor results. Here, we show that SU5416 is also an aryl hydrocarbon receptor
Hidenori Moriyama et al.
Nature communications, 13(1), 3013-3013 (2022-06-01)
Pulmonary hypertension is a fatal rare disease that causes right heart failure by elevated pulmonary arterial resistance. There is an unmet medical need for the development of therapeutics focusing on the pulmonary vascular remodeling. Bioactive lipids produced by perivascular inflammatory
Yong Liu et al.
Journal of orthopaedic translation, 23, 29-37 (2020-06-02)
Accelerating the process of bone regeneration is of great interest for surgeons and basic scientists alike. Recently, umbilical cord mesenchymal stem cells (UCMSCs) are considered clinically applicable for tissue regeneration due to their noninvasive harvesting and better viability. Nonetheless, the
Xiaowei Nie et al.
Journal of hypertension, 35(12), 2419-2435 (2017-07-14)
Similar to cancer, pulmonary arterial hypertension (PAH) is characterized by vascular remodeling, which leads to obliteration of the small pulmonary arteriole, with marked proliferation of pulmonary artery smooth muscle cells (PASMC) and/or endothelial cells dysfunction. Aberrant expression of tumor suppressor
Loredana Ciuclan et al.
American journal of respiratory and critical care medicine, 184(10), 1171-1182 (2011-08-27)
The complex pathologies associated with severe pulmonary arterial hypertension (PAH) in humans have been a challenge to reproduce in mice due to the subtle phenotype displayed to PAH stimuli. Here we aim to develop a novel murine model of PAH

Articles

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique